Key terms
About CRBU
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRBU news
Apr 08
3:25am ET
Buy Rating Affirmed: Caribou Biosciences’ Promising Trials and Strategic Market Positioning
Apr 05
8:41am ET
Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Icon (ICLR) and Teladoc (TDOC)
Apr 05
5:40am ET
Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)
Apr 05
5:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Paragon 28 (FNA), Caribou Biosciences (CRBU)
Apr 04
4:24pm ET
Caribou Biosciences Advances with FDA Clearance and New Trials
Apr 04
4:06pm ET
FDA clears Caribou’s IND application for CB-010 to treat lupus and ERL
Mar 19
6:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)
Mar 19
6:14am ET
Caribou Biosciences price target raised to $24 from $23 at H.C. Wainwright
Mar 14
2:29pm ET
Caribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry Point
Mar 13
7:35am ET
Caribou Biosciences (CRBU) Gets a Buy from Truist Financial
Mar 13
6:20am ET
Caribou should be bought on ‘illogical weakness,’ says Citi
Mar 13
5:50am ET
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Medtronic (MDT) and Caribou Biosciences (CRBU)
Mar 13
1:55am ET
Optimistic Outlook for Caribou Biosciences with a Buy Rating and $20 Price Target
Mar 12
6:46am ET
RBC Capital Remains a Buy on Caribou Biosciences (CRBU)
Mar 11
4:27pm ET
Caribou Biosciences reports Q4 EPS (39c), consensus (37c)
Feb 20
7:20am ET
Precision BioSciences in non-exclusive patent license deal with Caribou
Jan 31
5:55am ET
Caribou Biosciences management to meet with Truist
Jan 30
4:55am ET
Caribou Biosciences management to meet with Truist
Jan 25
8:03am ET
Caribou Biosciences management to meet with Truist
Jan 18
8:47pm ET
RBC Capital Keeps Their Buy Rating on Caribou Biosciences (CRBU)
Jan 08
1:02pm ET
Edgewise, Caribou higher after WSJ report of Cytokinetics buyout
Jan 08
7:34am ET
Allogene Therapeutics price target lowered to $17 from $18 at Truist
Jan 08
7:31am ET
Caribou Biosciences price target lowered to $21 from $23 at Truist
No recent press releases are available for CRBU
CRBU Financials
Key terms
Ad Feedback
CRBU Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRBU Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
